TransMedics Reports Q1 2026 Earnings with Revenue Growth and Strategic Investments

TransMedics (TMDX) reported Q1 2026 earnings with total revenue of $174 million, reflecting 21% year-over-year growth. The company highlighted strong performance in transplant product and logistics services revenue, along with a 10.4% adjusted operating margin. TransMedics also noted significant investments in growth initiatives, including the OCS platform and international expansion.

By Motley Fool Transcribing · Motley Fool · May 6, 2026, 14:21 UTC

Tickers: $TMDX

Topics: cash reserves operating profit R&D revenue SG&A transplant products

Read the full article at Motley Fool

More World news

Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC